Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
CATALYST PHARMACEUTICALS, INC. completed an acquisition involving Santhera Pharmaceuticals Holdings AG for all-cash purchase payment of $75 million; strategic equity investment of approximately $15 million in Santhera ordinary shares; potential milestone payments and (closed 2023-07-19).
- Action
- acquisition
- Counterparty
- Santhera Pharmaceuticals Holdings AG
- Consideration
- all-cash purchase payment of $75 million; strategic equity investment of approximately $15 million in Santhera ordinary shares; potential milestone payments and
- Closing
- 2023-07-19
Exact text from the filing
Item 2.01 Completion of Acquisition or Disposition of Assets On July 19, 2023, Catalyst Pharmaceuticals, Inc. (the “ Company ”) completed its acquisition from Santhera Pharmaceuticals Holdings AG (“ Santhera ”) of an exclusive license for North America for vamorolone, a potential treatment for patients suffering with Duchenne Muscular Dystrophy (“ DMD ”). The license is for exclusive commercial rights in the U.S., Canada, and Mexico, as well as the right of first negotiation in Europe and Japan should Santhera pursue partnership opportunities. Additionally, the Company will hold North American rights for any future approved indications of vamorolone. As previously disclosed, the Company will make an all-cash purchase payment of $75 million to acquire the license pursuant to a License Agreement, dated June 19, 2023, by and between Santhera, its wholly owned subsidiary, Santhera Pharmaceuticals (Schweiz) AG, and the Company (the “ License Agreement ”). Simultaneously, pursuant to an Inve
View on SEC.gov